Tyr321
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Tyr321  -  TAZ (human)

Site Information
sGLGLGCySVPTtPE   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 27138200

In vivo Characterization
Methods used to characterize site in vivo:
mutation of modification site ( 1 ) , western blotting ( 1 )
Disease tissue studied:
lung cancer ( 1 ) , non-small cell lung cancer ( 1 ) , non-small cell lung adenocarcinoma ( 1 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Putative in vivo kinases:
Arg (human) ( 1 )
Treatments:
doxycycline ( 1 )

Downstream Regulation
Effects of modification on TAZ:
intracellular localization ( 1 )
Effects of modification on biological processes:
carcinogenesis, altered ( 1 ) , signaling pathway regulation ( 1 ) , transcription, induced ( 1 )

References 

1

Hoj JP, Mayro B, Pendergast AM (2019) A TAZ-AXL-ABL2 Feed-Forward Signaling Axis Promotes Lung Adenocarcinoma Brain Metastasis. Cell Rep 29, 3421-3434.e8
31825826   Curated Info

2

Kimura T, et al. (2019) GDP-Bound Rab27a Dissociates from the Endocytic Machinery in a Phosphorylation-Dependent Manner after Insulin Secretion. Biol Pharm Bull 42, 1532-1537
31474712   Curated Info